Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Table 4 Usefulness of liver stiffness measurement compared with liver biopsy in the detection of fibrosis in nonalcoholic fatty liver disease patients

Study	Probe	Cut-off (kPa)	Sensitivity	Specificity	Number of patients with liver biopsy
Fibrosis stage ≥ F2
Imajo et al[83] (2016)	M	11.0	61.7	100	142
Pathik et al[84] (2015)	M	9.1	Not reported	Not reported	110
Yoneda et al[87] (2007)	M	6.65	81.8	91.2	67
Cassinotto et al[88] (2015)	M	6.2	≥ 90	Not available	291
Wong et al[89] (2010)	M	7.0	88	74	246
Lupsor et al[90] (2010)	M	6.8	67	84	72
Yoneda et al[91] (2008)	M	6.65	88	74	97
Kumar et al[92] (2013)	M	7.0	78	79	205
Fibrosis stage ≥ F3
Imajo et al[83] (2016)	M	11.4	85.7	83.8	142
Pathik et al[84] (2015)	M	12.0	90	80	110
Yoneda et al[87] (2007)	M	8.0	87.5	84.3	67
Cassinotto et al[88] (2015)	M	8.2	≥ 90	Not available	291
Wong et al[89] (2010)	M	8.7	84	83	246
Lupsor et al[90] (2010)	M	10.4	100	97	72
Yoneda et al[91] (2008)	M	9.8	85	81	97
Kumar et al[92] (2013)	M	9.0	85	88	205
Fibrosis stage F4
Imajo et al[83] (2016)	M	14.0	100	75.9	142
Pathik et al[84] (2015)	M	20.0	90	80	110
Yoneda et al[87] (2007)	M	17.0	100	98.4	67
Cassinotto et al[88] (2015)	M	9.5	≥ 90	Not available	291
Wong et al[89] (2010)	M	10.3	92	97	246
Yoneda et al[91] (2008)	M	17.5	100	97	97
Kumar et al[92] (2013)	M	11.8	90	88	205